A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer

BACKGROUND: Preclinical models show that an antiangiogenic regimen at low-dose daily (metronomic) dosing may be effective against chemotherapy-resistant tumors. We undertook a prospective, open-label, single-arm, multi-institutional phase II study to evaluate the efficacy of a “5-drug” oral regimen...

Descripción completa

Detalles Bibliográficos
Autores principales: Robison, Nathan J, Campigotto, Federico, Chi, Susan N, Manley, Peter E, Turner, Christopher D, Zimmerman, Mary Ann, Chordas, Christine A, Werger, Annette M, Allen, Jeffrey C, Goldman, Stewart, Rubin, Joshua B, Isakoff, Michael S, Pan, Wilbur J, Khatib, Ziad A, Comito, Melanie A, Bendel, Anne E, Pietrantonio, Jay B, Kondrat, Laura, Hubbs, Shannon M, Neuberg, Donna S, Kieran, Mark W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285784/
https://www.ncbi.nlm.nih.gov/pubmed/24123865
http://dx.doi.org/10.1002/pbc.24794

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285784/
https://www.ncbi.nlm.nih.gov/pubmed/24123865
http://dx.doi.org/10.1002/pbc.24794

Ejemplares similares